Key Investor Signals
Licensed university organoid and AI technology
The University of Barcelona and Pompeu Fabra University established OrganAID in 2025, with licensed technology combining patient-derived tissue models and predictive image analysis.
Won a place in ChemoStart’s ninth edition
OrganAID was one of two winners of pharmaceutical group Insud Pharma’s ChemoStart program, which provides tailored scientific and business-development support.
Vueling and Iryo co-founder leads OrganAID as CEO
Co-founder and CEO Víctor Bañares previously co-founded airline Vueling and high-speed rail operator Iryo, bringing company-building experience to the scientific team.
Other Positive Signals
- Received university and public research-transfer support for market studies and patentability analysis.
Team
Sandra Acosta
Co-founder
- University of Barcelona professor with over 15 years of experience modeling neurological disorders in laboratory systems.
- Associate scientist at Sant Joan de Déu Hospital and the Pasqual Maragall Foundation, specializing in neurodegeneration and genomics.
- Leads the Brain Disorders Models Research Group at BBRC and Sant Joan de Déu, using brain organoids to study neurodegeneration.
Óscar Lao
Co-founder
- Senior scientist at CSIC and professor at ESCI-UPF, with over 20 years developing computational tools for human genetics.
- Co-authored more than 60 scientific papers on human genetic variation, population genomics and bioinformatics.
- Completed nine years of postdoctoral research in forensic molecular biology at Erasmus MC, focused on human genetic variation.
Víctor Bañares
Co-founder & CEO
- Co-founded Vueling and Iryo, bringing experience building airline and high-speed rail businesses.
- Held senior leadership roles across Renfe AVE, Vueling, Air Europa and Iryo, spanning aviation and high-speed rail operations.
- Founded N634 Capital after 30 years in transport and mobility, extending his operator experience into investment and company creation.
Product
OrganAID combines patient-derived organoids with a multistep AI analysis of images collected during laboratory drug tests. The workflow selects suitable tissue models, assesses toxicity and measures treatment effects while retaining patient-specific biological variation.
Patient-specific tissue models
The laboratory generates brain organoids from reprogrammed patient cells or tumor biopsies. These three-dimensional cultures reproduce selected features of diseased tissue and provide a model for testing candidate treatments.
Image-based drug assessment
AI analyzes static and live images of the tissue models. The multistep process evaluates model suitability, changes associated with toxicity and potential treatment effects to support laboratory drug testing.
Research cells and testing services
The service catalogue includes drug testing in cerebral, colonic and retinal tissue models, alongside production of personalized cells and organoids. Disease-specific models include neurological conditions and cancers.
Market Overview
Neurological drug development is difficult because laboratory models do not fully reproduce human brain biology or patient variation. Patient-derived tissue models can support earlier testing of efficacy and toxicity, while reproducibility, maturation and clinical relevance remain important validation challenges.
Pharmaceutical and biotechnology developers purchase laboratory models and testing services to evaluate compounds before and during development. Regulators are expanding pathways for qualified alternatives to animal studies. Commercial adoption depends on robust assays, useful turnaround times and evidence that results improve development decisions.
An estimated 3.40 billion people had a condition affecting the nervous system globally in 2021.
The estimated likelihood of FDA approval from Phase I across programs studied during 2011–2020.
Average time for a Phase I drug asset to reach regulatory approval in the 2011–2020 development analysis.
Active submissions in FDA’s qualification pathway for innovative nonclinical methods as of April 2026.
Comparable Outcomes
MatTek
Developed and manufactured human cell-based 3D tissue models and primary cells used for in vitro testing as alternatives to animal studies. CELLINK completed its purchase of MatTek in March 2021. Its interim accounts recorded SEK 614.9M in purchase consideration for the tissue-model business.
ZenBio
Supplied primary human fat cells, culture media and cell-based assays used to test compounds for obesity and diabetes. BioIVT acquired ZenBio in August 2024, expanding its portfolio of primary cells, tissue expertise and laboratory research services.
Interested in More Startups Like OrganAID?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.